Chronic hepatitis C treatment in a cystic fibrosis patient in the pulmonary pre-transplant stage
| Autor: | F. Gea Rodríguez, L. Adán Merino, C. Prados, P. Castillo Grau, A. Olveira Martín, E. Martín Arranz, J. C. Sáenz, J. M. Segura Cabral |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male medicine.medical_specialty Cystic Fibrosis Hepatitis C virus medicine.disease_cause Antiviral Agents Gastroenterology Cystic fibrosis Pulmonary function testing chemistry.chemical_compound Internal medicine Ribavirin medicine Humans Lung Respiratory tract infections business.industry Standard treatment Respiratory infections General Medicine Hepatitis C Hepatitis C Chronic medicine.disease Surgery Portal System medicine.anatomical_structure Liver chemistry Drug Therapy Combination Interferons business Pegylated interferon Lung Transplantation Lung transplant |
| Zdroj: | Revista Española de Enfermedades Digestivas v.102 n.10 2010 SciELO España. Revistas Científicas Españolas de Ciencias de la Salud instname |
| Popis: | The standard treatment of chronic hepatitis C, pegylated inter feron and ribavirin (pegI/R), has many limitations in both effec tiveness and secondary effects, which makes it unsuitable or even contraindicated for some patients. In hepatitis C virus-infected cystic fibrosis patients this treatment could increase respiratory in fections with subsequent pulmonary function deterioration. On the contrary, hepatitis C virus (HCV) infection may make lung transplant (LT) unfeasible. We present the case of a cystic fibrosisyoung man diagnosed with HCV infection during LT assessment who was treated with pegI/R. In spite of the lung function wors ening and respiratory infections, he managed to complete treat ment and even sustained virological response (SVR). At present he is on LT waiting list. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|